Main Street Group’s Scinai Immunotherapeutics SCNI Stock Holding History

Main Street Group’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20	Closed	-$59	–	852
2024 Q2	$59	Hold	20	–	–	﹤0.01%	858
2024 Q1	$103	Hold	20	–	–	﹤0.01%	895
2023 Q4	$119	Buy	+20	New	+$138	﹤0.01%	1261

Other funds holding SCNI

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Main Street Group's SCNI Position: Q3 2024 in Review

Main Street Group sold out of Scinai Immunotherapeutics (SCNI) in Q3 2024, closing a stake of 20 shares — an estimated $59 sold.

Main Street Group first reported a position in SCNI in Q4 2023 and held it in 3 quarters. The position peaked at $119 in Q4 2023. 5 funds tracked by Wall St. Rank hold SCNI as of Q3 2024.

Main Street Group reported no remaining Scinai Immunotherapeutics position as of Q3 2024 after selling out during the quarter.
Main Street Group sold 20 Scinai Immunotherapeutics shares in Q3 2024, an estimated $59.
Main Street Group first reported a position in Scinai Immunotherapeutics in Q4 2023 and held it in 3 quarters.
Main Street Group's Scinai Immunotherapeutics position peaked at $119 in Q4 2023.
5 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2024.

Based on Main Street Group's 13F filing for Q3 2024, filed 13 Nov 2024.